Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.
Cells. 2024 Jun 1;13(11):960. doi: 10.3390/cells13110960.
Binge drinking in obese patients positively correlates with accelerated liver damage and liver-related death. However, the underlying mechanism and the effect of alcohol use on the progression of metabolic-dysfunction-associated steatotic liver disease (MASLD) remain unexplored. Here, we show that short-term feeding of a metabolic-dysfunction-associated steatohepatitis (MASH) diet plus daily acute alcohol binges for three days induce liver injury and activation of the NLRP3 inflammasome. We identify that a MASH diet plus acute alcohol binges promote liver inflammation via increased infiltration of monocyte-derived macrophages, neutrophil recruitment, and NET release in the liver. Our results suggest that both monocyte-derived macrophages and neutrophils are activated via NLRP3, while the administration of MCC950, an NLRP3 inhibitor, dampens these effects.In this study, we reveal important intercellular communication between hepatocytes and neutrophils. We discover that the MASH diet plus alcohol induces IL-1β via NLRP3 activation and that IL-1β acts on hepatocytes and promotes the production of CXCL1 and LCN2. In turn, the increase in these neutrophils recruits chemokines and causes further infiltration and activation of neutrophils in the liver. In vivo administration of the NLRP3 inhibitor, MCC950, improves the early phase of MetALD by preventing liver damage, steatosis, inflammation, and immune cells recruitment.
酗酒与肥胖患者的肝损伤和与肝相关的死亡呈正相关。然而,酒精使用对代谢功能障碍相关脂肪性肝病(MASLD)进展的潜在机制和影响仍未被探索。在这里,我们表明,代谢功能障碍相关脂肪性肝炎(MASH)饮食加每日急性酒精狂欢三天可导致肝损伤和 NLRP3 炎性体的激活。我们发现,MASH 饮食加急性酒精狂欢通过增加单核细胞来源的巨噬细胞、中性粒细胞募集和 NET 在肝脏中的释放来促进肝脏炎症。我们的结果表明,单核细胞来源的巨噬细胞和中性粒细胞都通过 NLRP3 被激活,而 NLRP3 抑制剂 MCC950 的给药抑制了这些作用。在这项研究中,我们揭示了肝细胞和中性粒细胞之间重要的细胞间通讯。我们发现,MASH 饮食加酒精通过 NLRP3 激活诱导 IL-1β,并且 IL-1β 作用于肝细胞并促进 CXCL1 和 LCN2 的产生。反过来,这些中性粒细胞的增加招募趋化因子,并导致肝脏中中性粒细胞的进一步浸润和激活。体内给予 NLRP3 抑制剂 MCC950 通过防止肝损伤、脂肪变性、炎症和免疫细胞募集来改善 MetALD 的早期阶段。